Bio-Techne (TECH) Expected to Announce Earnings on Wednesday

Bio-Techne (NASDAQ:TECH) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of $0.38 per share and revenue of $285.84 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Bio-Techne Stock Performance

NASDAQ TECH opened at $73.55 on Monday. The stock has a market cap of $11.69 billion, a PE ratio of 78.25, a P/E/G ratio of 5.30 and a beta of 1.27. Bio-Techne has a twelve month low of $61.16 and a twelve month high of $85.57. The stock has a fifty day simple moving average of $74.72 and a 200-day simple moving average of $74.41. The company has a current ratio of 4.56, a quick ratio of 3.26 and a debt-to-equity ratio of 0.14.

Insider Activity at Bio-Techne

In other news, CEO Kim Kelderman sold 13,392 shares of the company’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $77.29, for a total transaction of $1,035,067.68. Following the completion of the transaction, the chief executive officer now directly owns 39,004 shares of the company’s stock, valued at approximately $3,014,619.16. This represents a 25.56 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on TECH shares. StockNews.com upgraded shares of Bio-Techne from a “hold” rating to a “buy” rating in a research note on Tuesday, November 12th. Robert W. Baird upped their target price on shares of Bio-Techne from $82.00 to $84.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Finally, Scotiabank raised their price target on shares of Bio-Techne from $83.00 to $88.00 and gave the company a “sector outperform” rating in a research report on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Bio-Techne presently has an average rating of “Moderate Buy” and a consensus price target of $84.00.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.